{"id":"NCT00811798","sponsor":"GlaxoSmithKline","briefTitle":"Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.","officialTitle":"Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Subjects.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-05","primaryCompletion":"2010-09","completion":"2010-09","firstPosted":"2008-12-19","resultsPosted":"2011-10-13","lastUpdate":"2016-10-20"},"enrollment":92,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Papillomavirus"],"interventions":[{"type":"BIOLOGICAL","name":"Cervarix","otherNames":[]}],"arms":[{"label":"Cervarix Group","type":"EXPERIMENTAL"}],"summary":"This study will collect safety data of GlaxoSmithKline Biologicals' human papillomavirus (HPV) vaccine in healthy females of Chinese origin who are unable to receive all three doses of commercially available HPV vaccine before they are 25 years, and were placebo recipients in the primary study (NCT00306241).","primaryOutcome":{"measure":"Number of Subjects Reporting Any Serious Adverse Event (SAE) and SAE(s) With a Causal Relationship to Vaccination as Assessed by the Investigator.","timeFrame":"During the entire study period (Day 0 up to the telephone contact at Month 12).","effectByArm":[{"arm":"Cervarix Group","deltaMin":3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"25 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":12},"locations":{"siteCount":1,"countries":["Hong Kong"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":92},"commonTop":[]}}